Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
PD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors. Blocking the PD-1/PD-L1 pathway can reshape the tumor microenvironment or block the formation of the tumor microenvironment and enhan...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.918709/full |
| _version_ | 1828212922017382400 |
|---|---|
| author | Feng Li Feng Li Binchi Liao Ting Wang Tingting Qi Yixin Wang |
| author_facet | Feng Li Feng Li Binchi Liao Ting Wang Tingting Qi Yixin Wang |
| author_sort | Feng Li |
| collection | DOAJ |
| description | PD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors. Blocking the PD-1/PD-L1 pathway can reshape the tumor microenvironment or block the formation of the tumor microenvironment and enhance endogenous antitumor immune response. Clinical trials show that the treatment of non-small cell lung cancer (NSCLC) with PD-1/PD-L1 inhibitors has significant advantages. The review briefly describes these basic principles of the PD-1/PD-L1 pathway and action mechanism in the treatment of NSCLC. A summary of global PD-1/PD-L1 clinical trials and five PD-1/PD-L1 inhibitors approved by FDA, EMA and NMPA for advanced NSCLC were analyzed. |
| first_indexed | 2024-04-12T14:44:03Z |
| format | Article |
| id | doaj.art-16e6ecdd8af9404e9917a312f7347826 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T14:44:03Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-16e6ecdd8af9404e9917a312f73478262022-12-22T03:28:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-06-011310.3389/fphar.2022.918709918709Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in TreatmentFeng Li0Feng Li1Binchi Liao2Ting Wang3Tingting Qi4Yixin Wang5Sichuan Cancer Hospital, Cancer Hospital Affiliate to School of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaNational Medical Products Administration Institute of Executive Development, Beijing, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate to School of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate to School of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate to School of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaPD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors. Blocking the PD-1/PD-L1 pathway can reshape the tumor microenvironment or block the formation of the tumor microenvironment and enhance endogenous antitumor immune response. Clinical trials show that the treatment of non-small cell lung cancer (NSCLC) with PD-1/PD-L1 inhibitors has significant advantages. The review briefly describes these basic principles of the PD-1/PD-L1 pathway and action mechanism in the treatment of NSCLC. A summary of global PD-1/PD-L1 clinical trials and five PD-1/PD-L1 inhibitors approved by FDA, EMA and NMPA for advanced NSCLC were analyzed.https://www.frontiersin.org/articles/10.3389/fphar.2022.918709/fullPD-1/PD-L1 inhibitorsNSCLCclinical trialsadverse Reactionsimmunity therapy |
| spellingShingle | Feng Li Feng Li Binchi Liao Ting Wang Tingting Qi Yixin Wang Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment Frontiers in Pharmacology PD-1/PD-L1 inhibitors NSCLC clinical trials adverse Reactions immunity therapy |
| title | Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment |
| title_full | Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment |
| title_fullStr | Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment |
| title_full_unstemmed | Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment |
| title_short | Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment |
| title_sort | programmed cell death protein 1 programmed cell death protein ligand 1 immunosuppressants in advanced non small cell lung cancer research progress in treatment |
| topic | PD-1/PD-L1 inhibitors NSCLC clinical trials adverse Reactions immunity therapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.918709/full |
| work_keys_str_mv | AT fengli programmedcelldeathprotein1programmedcelldeathproteinligand1immunosuppressantsinadvancednonsmallcelllungcancerresearchprogressintreatment AT fengli programmedcelldeathprotein1programmedcelldeathproteinligand1immunosuppressantsinadvancednonsmallcelllungcancerresearchprogressintreatment AT binchiliao programmedcelldeathprotein1programmedcelldeathproteinligand1immunosuppressantsinadvancednonsmallcelllungcancerresearchprogressintreatment AT tingwang programmedcelldeathprotein1programmedcelldeathproteinligand1immunosuppressantsinadvancednonsmallcelllungcancerresearchprogressintreatment AT tingtingqi programmedcelldeathprotein1programmedcelldeathproteinligand1immunosuppressantsinadvancednonsmallcelllungcancerresearchprogressintreatment AT yixinwang programmedcelldeathprotein1programmedcelldeathproteinligand1immunosuppressantsinadvancednonsmallcelllungcancerresearchprogressintreatment |